000			03789nam a2200469 a 4500
001			vtls000051048
003			KUKTEM
005			20251117141416.0
006			m f d
007			cr mnu---uuuuu
008			110110t2009 dcua fob 000 0 eng d
020			_a9780309130394
020			_a0309130395
020			_a9780309130400 (electronic bk.)
020			_a0309130409 (electronic bk.)
020			_a9786612239243
020			_a6612239247
039		9	_a201107131657 _bVLOAD _c201105101022 _djamie _c201105100959 _dida _c201105091524 _djamie _y201101101221 _zida _wimport 2.mrk _x605
040			_aUMP
090			_aQD181.U7 M43 2009
245	0	0	_aMedical isotope production without highly enriched uranium _h[electronic resource] / _cCommittee on Medical Isotope Production Without Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division of Earth and Life Studies, National Research Council of the National Academies
260			_aWashington, D.C. : _bNational Academies Press, _cc2009
300			_a1 electronic text (xviii, 202 p.) : _bdigital, GIF, PDF, ill.
500			_aTitle from electronic title page (viewed June 1, 2009)
504			_aIncludes bibliographical references
505	0		_aBackground and study task -- Molybdenum-99/Technetium-99m production and use -- Molybdenum-99/Technetium-99m supply -- Molybdenum-99/Technetium-99m supply reliability -- Molybdenum-99/Technetium-99m demand -- Molybdenum-99/Technetium-99m production costs -- Conversion to LEU-based production of Molybdenum-99: technical considerations -- Conversion to LEU-based production of Molybdenum-99: regulatory considerations -- Conversion to LEU-based production of Molybdenum-99: general approaches and timing -- Conversion to LEU-based production of Molybdenum-99: prospects and feasibility
516			_aText in GIF and PDF format
520			_a"This book is the product of a congressionally mandated study to examine the feasibility of eliminating the use of highly enriched uranium (HEU2) in reactor fuel, reactor targets, and medical isotope production facilities. The book focuses primarily on the use of HEU for the production of the medical isotope molybdenum-99 (Mo-99), whose decay product, technetium-99m3 (Tc-99m), is used in the majority of medical diagnostic imaging procedures in the United States, and secondarily on the use of HEU for research and test reactor fuel. The supply of Mo-99 in the U.S. is likely to be unreliable until newer production sources come online. The reliability of the current supply system is an important medical isotope concern; this book concludes that achieving a cost difference of less than 10 percent in facilities that will need to convert from HEU- to LEU-based Mo-99 production is much less important than is reliability of supply"
538			_aMode of access : Internet
650		0	_aMolybdenum _xSupply & distribution _zUnited States
650		0	_aMolybedenum _xIsolation & purification _zUnited States
650		0	_aRadioisotopes _xsupply & distribution _zUnited States
650		0	_aTechnetium Compounds _xisolation & purification _zUnited States
650		0	_aUranium _xIsotopes
650		0	_aUranium _xIsotopes _xTherapeutic use
650		0	_aMolybdenum _xIsotopes _xTherapeutic use
650		0	_aTechnetium _xIsotopes _xTherapeutic use
710	2		_aNational Research Council (U.S.). _bCommittee on Medical Isotope Production Without Highlty Enriched Uranium
856	4	0	_3NetLibrary _uhttp://www.netlibrary.com.libraryumpsa.idm.oclc.org/urlapi.asp?action=summary&v=1&bookid=285289
999			_z634293014559499162 _c16348 _d16354
999			_aVIRTUA40
999			_aVTLSSORT0060*0070*0080*0200*0201*0202*0203*0204*0205*0400*0900*2450*2600*3000*5000*5040*5050*5160*5200*5380*6500*6501*6502*6503*6504*6505*6506*6507*7100*8560*9992